Could a few minutes of low oxygen help you sleep better?
NCT ID NCT07394699
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether short, controlled sessions of low-oxygen breathing (intermittent hypoxia) can improve sleep in people with primary insomnia. Thirty adults aged 18 to 60 who are not taking sleep medications will be randomly assigned to receive either the real low-oxygen treatment or a sham version (normal air) twice daily for a week. Researchers will measure sleep quality using overnight sleep studies and questionnaires.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- intermittent hypoxia (controlled low-oxygen breathing)
- What this could lead to
- If it works, this could offer a new, drug-free way to improve sleep for people with insomnia.
- What could go wrong
- This is a very small, early study with only 30 people. The approach is experimental and may not work or could cause discomfort. Results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects are diagnosed with primary insomnia between 18 and 60 years old，gender is not limited. * Patients who are not taking sedative-hypnotic drugs or have stopped taking drugs for more than 2 weeks. * Residing in the plains all year round and not having been above 1500 meters above sea level in the past 30 days. * Quiet state SaO2 ≥ 90%, cerebral oxygen saturation 58-82%, heart rate 60-100 beats/min, blood pressure 90-140/60-90 mmHg, respiratory rate 16-20 times/min. * No functional drinks, caffeine-containing beverages, or sleep-disturbing medications during the study period. Exclusion Criteria: * Stroke onset in the past 3 months, other severe neurological diseases, such as epilepsy, intracranial infectious diseases or demyelination. * Uncontrolled hypertension (systolic blood pressure ≥200mmHg) with antihypertensive drugs before enrollment, other cardiovascular diseases. * History of pulmonary, hepatic, dermatologic, or hematologic diseases. * History of substance abuse. * Pregnancy, Severe sleep apnea and neurological disorders.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Insomnia, primary are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.